Randomized Trial
A randomized trial: “Prevention of Asthma in Childhood (the PAC study)” [1] was nested in the COPSAC2000 cohort.
Participants were randomly assigned to either 400μg inhaled Budesonid per day or matching placebo for a two week period beginning day three of any episode of wheezing.
The primary outcome was the number of symptom-free days; key secondary outcomes were the time to discontinuation due to persistent wheezing and safety, as evaluated by height and bone mineral density at the end of the study.
The study showed that intermittent inhaled corticosteroid therapy had no effect on the progression from episodic to persistent wheezing and no short-term benefit during episodes of wheezing in the first three years of life.
